We studied in detail the immunological response to vaccination with mRNA-electroporated DC in 2 cohorts of melanoma patients: as palliative treatment for distant or irresectable locoregional metastatic disease and as adjuvant treatment following radical dissection of regional lymph nodes. A wide spectrum of tumor-specific IFNγ producing CD8 + T cells was detected, in particular in patients vaccinated in the adjuvant setting. Furthermore, vaccineinduced CD4 + T cells were shown to be FoxP3 negative.
Translational relevance
Electroporation of dendritic cells (DC) with mRNA encoding tumor associated antigens (TAA) has multiple advantages over the conventional peptide loading. The presentation of multiple naturally processed epitopes in both MHC Class I and II should broaden the repertoire of responding lymphocytes.
We studied in detail the immunological response to vaccination with mRNA-electroporated DC in 2 cohorts of melanoma patients: as palliative treatment for distant or irresectable locoregional metastatic disease and as adjuvant treatment following radical dissection of regional lymph nodes. A wide spectrum of tumor-specific IFNγ producing CD8 + T cells was detected, in particular in patients vaccinated in the adjuvant setting. Furthermore, vaccineinduced CD4 + T cells were shown to be FoxP3 negative.
In conclusion, vaccination with mRNA-electroporated DC successfully enhances anti-tumor cytotoxic T cell responses and appears to be a promising adjuvant treatment for stage III melanoma patients.
Introduction
Dendritic cells (DC) are the most effective antigen-presenting cells (APC) of the immune system, highly capable of stimulating naïve T cells. Immunotherapy with ex vivo-generated autologous DC pulsed with tumor peptides has provided proof of concept in clinical trials(1).
We, and others, have demonstrated that tumor-specific immune responses can be induced in both stage III and IV melanoma patients(1-5). Since objective clinical responses are observed in a minority of patients, further optimization of DC based immunotherapy is warranted.
To date, the majority of clinical studies on DC based vaccinations have been performed with MHC class I restricted peptide-pulsed monocyte derived DC in patients with measurable distant metastatic disease. However, there are at least several theoretical disadvantages against these protocols, which might be improved to induce more effective and sustained immunological responses. First, the exploitation of MHC class I restricted peptide epitopes target CD8 + cytotoxic T cells (CTL) only, without involving CD4 + T helper cells to enhance and sustain anti-tumor CTL responses. Secondly, pulsing DC with peptide epitopes implicates the use of a given HLA type, with defined tumor associated antigens (TAA).
Moreover, peptide-loaded DC expose the antigen only for a short period of time(6), since the peptides may readily dissociate from the MHC molecules(7). Importantly, peptide loading does not account for post-transcriptional modifications of peptide epitopes(8;9).
One strategy to circumvent most of these disadvantages of peptide pulsing is electroporation with synthetic mRNA encoding TAA, resulting in endogenous synthesis of the complete TAA.
It has been shown previously that electroporation of DC with mRNA is effective and safe(7;10;11). DCs retain their phenotype and maturation potential upon electroporation, as well as their migratory capacities(10;12). Electroporated DC express TAA antigens, encoded by the electroporated mRNA and induce specific CD8 + T cell responses in melanoma
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It is now widely recognized that high tumorload in end-stage cancer patients often induces local, or even systemic, immune suppression by the secretion of suppressive cytokines and attraction of regulatory T cells (13) (14) (15) . This suppressive tumor microenvironment will hamper the effective anti-tumor responses. Melanoma patients with locoregional lymph node metastases are at high risk of relapse and currently no standard adjuvant treatment is available which results in overall survival benefit(16). Given the minimal burden of tumor; we hypothesized that vaccination of patients adjuvant to therapeutic radical lymph node dissection might enhance vaccine efficacy.
In this study we investigated in detail the immunological responses to intranodal vaccination with monocyte-derived DC electroporated with mRNA encoding gp100 and tyrosinase in 2 cohorts of melanoma patients; with distant metastatic or irresectable locoregional disease following radical regional lymph node dissection.
Research. 
Patients and methods

Patient population
Melanoma patients with locoregional resectable disease (further referred to as stage III), before or within 2 months after radical dissection of regional lymph node metastases, and patients with irresectable locoregional or distant metastatic disease (further referred to as stage IV) were included. Additional inclusion criteria were HLA*02:01 phenotype, melanoma expressing the melanoma-associated antigens gp100 and tyrosinase, and WHO performance status 0 or 1. Patients with brain metastases, serious concomitant disease or a history of a second malignancy were excluded. The study was approved by our Institutional Review Board, and written informed consent was obtained from all patients. Clinical trial registration number is NCT00243529.
Study protocol
Patients received a DC vaccine intranodally, injected into a clinically tumor-free lymph node under ultrasound guidance. The DC vaccine consisted of autologous mature monocytederived DC electroporated with mRNA encoding for gp100 and tyrosinase protein, and pulsed with keyhole limped hemocyan (KLH) protein. Patients received three vaccinations with a biweekly interval. Ten patients received an extra vaccination 1 or 2 days before the radical lymph node dissection for additional imaging studies (manuscript in preparation). One to two weeks after the last vaccination a skin test was performed. In absence of disease progression or recurrence, patients received a maximum of two maintenance series at 6- Author Manuscript Published OnlineFirst on August 15, 2012; DOI: 10.1158/1078-0432.CCR-11-3368 specific immune response was the primary endpoint, clinical response was a secondary endpoint in stage IV patients. Progression-free and overall survival were calculated from the time from apheresis to recurrence (for stage III patients) or progression (for stage IV patients), or death.
DC preparation and characterization
DC were generated from peripheral blood mononuclear cells (PBMC) prepared from leukapheresis products as described previously(17). After leukapheresis, part of the PBMC was used for the generation of monocyte-conditioned medium (MCM)(18). Plastic-adherent monocytes or monocytes isolated by centrifugal elutriation were cultured for 5-7 days in X-
VIVO 15
TM medium (BioWhittaker, Walkersville, Maryland) supplemented with 2% pooled human serum (HS) (Bloodbank Rivierenland, Nijmegen, The Nethterlands), IL-4 (500 U/ml) and GM-CSF (800 U/ml) (both from Cellgenix, Freiburg, Germany). Immature DC were pulsed at day 3 with Keyhole limpet hemocyanin (KLH, 10 μg/ml; Calbiochem, San Diego, CA). Two days prior the harvesting, cells were matured with autologous MCM, prostaglandin E 2 (10 µg/ml; Pharmacia & Upjohn, Puurs, Belgium) and recombinant tumor necrosis factor alpha (10 ng/ml; provided by dr. G.Adolf, Bender Wien, Vienna, Austria)(19). This protocol gave rise to a mature phenotype meeting the release criteria described previously(20): low expression of CD14, high expression of MHC class I, MHC class II, CD83, CD80, CD86, and CCR7, and expression of gp100 and tyrosinase after electroporation with mRNA (Supplementary figure 2). Harvested DC were tested by FACS analysis as described below.
Plasmids and in vitro mRNA transcription
Plasmids have been sent to CureVac GmbH (Tübingen, Germany) for the production of documented GMP grade gp100 and tyrosinase RNA for ex vivo use in clinical DC vaccination. The documented gp100 and tyrosinase mRNA was produced from the plasmids pGEM4Z/hgp100/A64 and pGEM4Z/tyrosinase/A64 (provided by Kris Thielemans, Free University Brussels, Belgium) according to GMP guidelines. CureVac mRNA contains a 5' cap and 3' poly A-tail that leads to high RNA stability and increased protein expression in transfected cells. The mRNA is purified by PUREmessenger TM technology. This chromatography method efficiently eradicates traces of DNA and proteins. The mRNA production process is performed in clean room facilities and is documented by in-process controls. RNA quality was verified by agarose gel electrophoresis, RNA concentration was measured spectrophotometrically, and RNA was stored at -80ºC in small aliquots.
Electroporation of DC
Mature DC were electroporated as described previously(10). Briefly, DC were washed twice in PBS and once in OptiMEM without phenol red (Invitrogen, Breda, The Netherlands).
Twenty micrograms of RNA encoding either gp100 or tyrosinase were transferred to a 4 mm cuvette (Bio-Rad, Hercules, CA) and 8×10 6 cells were added in 200 µl OptiMEM and incubated for 3' before being pulsed in a Genepulser Xcell (Bio-Rad) by an exponential decay pulse of 300 V, 150 μF, as described before(10). Immediately after electroporation, cells were washed and were transferred to warm (37ºC) X-VIVO 15 TM without phenol red (Cambrex Bio Science, Verviers, Belgium) supplemented with 5% HS and left for at least 2 hours at 37ºC, before further manipulation. The first vaccination was given with fresh DC 4 hours after electroporation. DC for subsequent vaccinations were frozen 2 hours after electroporation, thawed at the day of vaccination and incubated for 2 more hours at 37°C before injection. Electroporation efficiency was analyzed by intracellular staining and flow cytometric analysis for each separate TAA, electroporated DC were mixed before vaccination.
KLH-specific antibody production
KLH-specific antibodies were measured in the sera of patients before and after vaccination.
Microtiter plates (96 wells) were coated overnight at 4ºC with KLH (25 µg/ml in PBS).
Different concentrations of patient serum (range 1:100 to 1:50,000) were added for 60' at room temperature. After extensive washing, patient antibodies were detected with mouse anti-human IgG, IgA, or IgM antibodies labelled with horseradish peroxidase (Invitrogen, San Diego, CA). 3,3' 5,5-tetramethyl-benzidine was used as a substrate and plates were measured with a microtiter plate reader at 450 nm. For quantification, an isotype-specific calibration curve for the KLH response was included in each microtiter plate.
Skin-test infiltrating lymphocyte (SKIL) cultures
-1 x 10
6 DC pulsed with the gp100 and/or tyrosinase peptides and DC electroporated with gp100 and/or tyrosinase mRNA each were injected i. 
Antigen and tumor recognition
Antigen recognition was determined by the production of cytokines and cytotoxic activity of SKILs in response to T2 pulsed with the indicated peptides or BLM (a melanoma cell line expressing HLA*02:01 but no endogenous expression of gp100 and tyrosinase), transfected with control antigen G250, with gp100 or tyrosinase, or an allogenic HLA*02:01-positive, gp100-positive, and tyrosinase-positive tumor cell line (MEL624) were measured. Cytokine production was measured in supernatants after 16 hours of co-culture by a cytrometric bead array (Th1/Th2 Cytokine CBA 1; BD PharMingen). Positive and specific cytokine production was defined as a two-fold increase compared to stimulation with the cell lines pulsed with an irrelevant peptide.
Statistical analysis
Differences between the groups were evaluated using the Fisher's exact test or one-way ANOVA. Statistical significance was defined as p<0.05. GraphPad Prism 5.0 was used for all analyses.
on Table 1 .
Vaccine characteristics
Phenotypic and functional release criteria were defined for DC vaccines to ensure minimal quality criteria and the usage of mature DC in clinical vaccination protocols(22). The phenotype of the ex vivo-generated DC was determined by flow cytometry and all produced vaccines met the standard release criteria, with respect to expression of MHC class I and II, and co-stimulatory molecules, CD83 and CCR7 (Supplementary figure 2a) . Furthermore, we confirmed the intracellular expression of tumor associated antigens gp100 and tyrosinase after electroporation by flow cytometry (Supplementary figure 2b) . Patients received on average 12×10 6 DC per vaccination with a maximum of 15×10 6 DC per vaccination.
Immunological response to KLH
For immunomonitoring purposes all DC have been loaded with the control antigen KLH.
PBMC, isolated after each vaccination, showed increased proliferation upon stimulation with KLH after vaccination in almost all patients in the first cycle (Figure 1a) . One patient first developed a proliferative response to KLH in the second cycle. Anti-KLH antibodies were detected in 9 out of 17 stage IV patients tested, and 15 out of 26 stage III patients tested (Figure 1b ). These data demonstrate that the vaccine effectively induced de novo immune responses.
Tumor-associated antigen specific responses in blood
To investigate TAA-specific immune responses, PBMC were screened with tetrameric-MHC complexes before and after each cycle of 3 vaccinations at the timepoint of SKIL test. TAAspecific CD8 + T cells were only found in freshly isolated PBMC from 3 stage III and 3 stage IV patients after vaccination ( Figure 2 and Table 2 ). Since it has been described that melanoma patients can already have a substantial number of TAA-specific T cells circulating in their blood, we analysed the presence of TAA-specific T cells in PBMC isolated prior to vaccination. Three out of these 6 patients had no detectable TAA-specific CD8 + T cells circulating before vaccination, suggesting that TAA-specific CD8 + T cells were newly induced, or at least enhanced, by the DC vaccinations in these patients, in concordance with previous reports(23).
Evidence is emerging that CD4 + T cells needs to be antigen-specific in order to potentiate the CD8 + immune response. Therefore we analysed the presence of TAA-specific CD4 + T cells in PBMCs of all 15 DR4 + patients. Four patients were positive after vaccination (patients IV-C-01, IV-C-02, IV-C-03, IV-C-08; Figure 3a and Table 2 ). Tetramer analysis of PBMCs restimulated in vitro with DR4-binding peptides confirmed the presence of TAA-specific CD4+
T cells ( Figure 3B ). TAA-specific CD4 + T cells were detectable before vaccination in only one Table 2 ). To exclude that the TAA-specific CD4 + T cells have a suppressor phenotype, we tested their FoxP3 expression, all were negative (Figure 3c ).
TAA-specific responses in skin-test infiltrating lymphocyte (SKIL) cultures
Previously we showed that the presence of TAA-specific T Figure 4b ). Strikingly, although we detected tetramer-specific CD8 + T cells in both stage III and IV melanoma patients to similar extend, we found increased IFNγ production only in 3 out of 11 stage IV melanoma patients.
Clinical responses in stage IV patients
All stage IV patients were evaluated for clinical response at 3-month intervals with CT scan. 
Long-lasting T cell receptor stimulation of several hours by fully matured DCs is necessary to activate naïve T cells to proliferate and differentiate into effector cells(25;26). The generated
DCs highly and sustainably expressed gp100 and tyrosinase after electroporation with mRNA. In vitro, DC were able to activate gp100-specific CTL up to 48 hours after electroporation. Previously, we demonstrated that gp100 and tyrosinase protein can be detected inside lymph nodes up to 24 hours after intranodal injection of mRNA electroporated DC(10). In this study, TAA-specific T cells were induced in the majority of patients which clearly demonstrates that electroporated DC are indeed potent inducers of tumor-specific T cells.
We detected TAA-specific CD8 + T cells in peripheral blood of only 6 of the 45 patients. This is an underestimation, likely due to the low frequencies of these cells in the circulation and the observation that substantially more TAA-specific CD8 + T cells were detected in SKIL cultures. Still, the number of TAA-specific T cells measured in this study might be underestimated because we screened with HLA*02:01 binding tetramers only. Indeed, in six patients SKILs produced IFNγ upon co-culture with the protein gp100 and/or tyrosinase, while no IFNγ production was detected upon co-culture with the corresponding HLA*02- when compared to patients with no vaccine-enhanced TAA-specific T cell responses. These data confirm and extend our previous findings that the presence of tumor-specific T cells in SKIL cultures identifies a subgroup of patients that might benefit from immunotherapy(21).
Moreover, these studies demonstrate that sustained disease control can be achieved in increasing numbers of patients, but objective anti-tumor responses might take several months to years to develop (44;45) . The, in general, delayed response patterns in immunotherapy and the high response rates to novel targeted therapies in melanoma, obviously warrants future studies that combine both modalities to achieve durable tumor IV- C-04  1  0  --------NED  8  22  IV-C-07  1  1  ----+++  ++  +  +  NED  46+  46+  IV-C-08  2  1  --+  -----NED  40+  40+  IV-C-10  2  1  ----+++  -++  -NED  37+  37+  IV-C-11  1  1  --------NED  36+  36+  IV-C-12  1  1  -+  -+  +  +  ++  +  NED  8 16
a Tetramer staining of freshly isolated PBMC or SKILs. -no recognition, + one epitope recognized, ++ two epitopes recognized, +++ three epitopes recognized. 
